The U.S. Federal Trade Commission said on Friday that it had approved generic drugmaker Mylan NV's planned purchase of Pfizer's Upjohn, subject to conditions.

Drugmaker Viatris Inc <a href=" target="_blank">(VTRS.O) said on Friday that its restructuring plans, announced earlier this year, could impact 20% of its workforce, or 9,000 employees.

Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals with other ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), formed from the 2020 merger of Mylan ...

The global oral contraceptive pills market was valued at US$ 18.55 Billion in 2023, grew to US$ 19.85 Billion in 2024, and is ...

Patients receiving ribociclib 400 mg had a shorter QTcF (12.5 vs 19.7 ms at cycle 1 day 15, 2 hours post-dose) and a lower rate of grade 3 or 4 neutropenia (41% vs 58.5%); they were also less likely ...

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy ...

Pfizer will buy Metsera for at least $47.50 per share. Pfizer could end up paying closer to $70 per share. Pfizer wants to sell GLP-1 weight loss drugs, and Metsera has four such candidates.

Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it’s acquiring Metsera, and its portfolio of four medications ...